Mainz Biomed Begins Feasibility Study on Pancreatic Cancer Detection

Mainz Biomed N.V. has launched a feasibility study in its PancAlert project, which aims to develop a non-invasive blood-based screening test for early pancreatic cancer detection. This phase seeks to confirm previous discovery results that showed 95% sensitivity and 98% specificity in detecting pancreatic cancer. Mainz Biomed collaborates with Crown Bioscience to verify a panel of mRNA biomarkers identified as clinically relevant.

The study will test these biomarkers and a machine learning algorithm under controlled conditions to evaluate their diagnostic performance. This step is crucial for assessing the assay's robustness and algorithm effectiveness in risk stratification. Depending on the feasibility study's outcome, Mainz Biomed plans to conduct a broader validation study, a critical step toward regulatory submissions and clinical readiness.